Loading…
Loading…
ENLV.TA (Enlivex Therapeutics Ltd.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
ENLV.TA does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ENLV.TA and 80,000+ other tickers.
See exactly how ENLV.TA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ENLV.TA and 80,000+ other tickers.
Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company specializing in immunotherapy through macrophage reprogramming. The company's primary therapeutic candidate, Allocetra, is a cell-based treatment currently in a Phase II clinical trial for organ dysfunction and failure linked to sepsis. Allocetra is also being investigated in preclinical studies for its application against solid tumors. Furthermore, Enlivex has partnered with BeiGene to evaluate Allocetra's safety and efficacy when administered alongside tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for advanced solid tumor patients. The company's headquarters are located in Ness Ziona, Israel.
No recent news available.